Statistik Asas
| CIK | 1817229 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Vor Biopharma Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| September 2, 2025 |
EX-99.1 Global Science. One Purpose. Corporate Presentation September 2025 Exhibit 99.1 Forward Looking Statement This presentation (the “Presentation”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. (“Vor,” “Vor Bio” or the “Company”). The words “aim,” “anticipate,” “believe,” “can,” “could,” “design,” “enabl |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 27, 2025 |
Up to $119,699,305 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-285969 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 31, 2025) Up to $119,699,305 Common Stock We have entered into a Sales Agreement, or the sale agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, dated December 23, 2022, relating to the sale of shares of our common stock, $0.0001 par value per shar |
|
| August 27, 2025 |
EX-10.1 Exhibit 10.1 VOR BIOPHARMA INC. AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JULY 28, 2025 APPROVED BY THE STOCKHOLDERS: AUGUST 25, 2025 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 7 6. ADJUSTMEN |
|
| August 12, 2025 |
Exhibit 10.10 500 BOYLSTON STREET BOSTON, MA OFFICE LEASE AGREEMENT BETWEEN 500 BOYLSTON & 222 BERKELEY OWNER (DE) LLC, a Delaware limited liability company, AS LANDLORD AND VOR BIOPHARMA, INC., a Delaware corporation, AS TENANT OFFICE LEASE AGREEMENT TABLE OF CONTENTS 1. Basic Lease Information. 1 2. Lease Grant. 3 3. Term and Commencement Date. 4 4. Rent. 5 5. Compliance with Laws; Use. 5 6. Gua |
|
| August 12, 2025 |
Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC. |
|
| August 8, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| July 29, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| July 22, 2025 |
EX-99.2 Exhibit 99.2 Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors July 21, 2025 - New board members bring decades of experience in company building, corporate strategy, commercialization, and business development CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transfor |
|
| July 22, 2025 |
Employment Agreement, dated as of July 17, 2025, by and between the Company and Qing Zuraw EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on July 17, 2025 by and between Qing Zuraw (the “Executive”) and Vor Biopharma Inc. (the “Company”). The Company desires to employ Executive and, in connection therewith, to compensate Executive for Executive’s personal services to the Company; and Executive wishes to be employed by the Company an |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| July 22, 2025 |
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer EX-99.1 Exhibit 99.1 Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer July 17, 2025 • Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience to support Vor Bio’s new development focus and execution of late-stage programs CAMBRIDGE, Mass., J |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| July 10, 2025 |
Employment Agreement, dated as of July 9, 2025, by and between the Company and Sandesh Mahatme. EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on July 9, 2025 by and between Sandy Mahatme (the “Executive”) and Vor Biopharma Inc. (the “Company”). The Company desires to employ Executive and, in connection therewith, to compensate Executive for Executive’s personal services to the Company; and Executive wishes to be employed by the Company |
|
| July 10, 2025 |
EX-99.1 Exhibit 99.1 Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer • Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support company’s transformation and growth in autoimmune disease CAMBRIDGE, Mass., July 10, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-sta |
|
| June 26, 2025 |
Employment Agreement, dated as of June 25, 2025, by and between the Company and Jean-Paul Kress. EX-10.7 Exhibit 10.7 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on June 25, 2025 by and between Jean-Paul Kress (the “Executive”) and Vor Biopharma Inc. (the “Company”). The Company desires to employ Executive and, in connection therewith, to compensate Executive for Executive’s personal services to the Company; and Executive wishes to be employed by the Compa |
|
| June 26, 2025 |
EX-10.5 Exhibit 10.5 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is entered into as of June 25, 2025 by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), and the stockholder of the Company named on the signature page hereto (the “Stockholder”). RECITALS A. Concurrently with the execution and delivery of this Agreement, the Company is enteri |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 26, 2025 |
Transition Agreement, dated as of June 25, 2025, by and between the Company and Robert Ang. Exhibit 10.6 June 25, 2025 Robert Ang Via Email Re: Transition Agreement Dear Robert: This letter sets forth the substance of the separation agreement (hereinafter, “Agreement”) which Vor Biopharma Inc. (hereinafter, “the Company”) is offering to you to aid in your employment transition. 1. Transition Period. You have tendered, and the Company hereby accepts, your resignation from your role as Chi |
|
| June 26, 2025 |
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset EX-99.1 Exhibit 99.1 Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset -Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis -RemeGen receives initial payment of $125 million consisting of an upfront payment |
|
| June 26, 2025 |
Exhibit 10.2 Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 25, 2025, by and among Vor Biop |
|
| June 26, 2025 |
Vor Bio Announces $175 Million Private Placement EX-99.2 Exhibit 99.2 Vor Bio Announces $175 Million Private Placement CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the “PIPE”) that is expected to result in |
|
| June 26, 2025 |
Form of Pre-Funded Warrant to Purchase Common Stock EX-10.1 Exhibit 10.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES |
|
| June 26, 2025 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 25, 2025, by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and delivering this |
|
| June 26, 2025 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 25, 2025, is entered into by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used here |
|
| May 23, 2025 |
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VOR BIOPHARMA INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Vor Biopharma Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), do |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC. |
|
| May 8, 2025 |
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value Exhibit 99.1 Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value CAMBRIDGE, Mass., May 8, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved |
|
| May 8, 2025 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 8, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 28, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted |
|
| March 27, 2025 |
VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140 VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140 March 27, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Lauren Hamill Re: Vor Biopharma Inc. Registration Statement on Form S-3 (File No. 333- 285969) Request for Acceleration of Effective Date Requested Date: March 31, 2025 Requested T |
|
| March 20, 2025 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The descriptions below of Vor Biopharma Inc.’s (“our” or “we”) common stock and provisions of our amended and restated certificate of incorporation (“Restated Certificate”) and amended and restated bylaws (“Bylaws”) are summaries and are qualified by reference to our Rest |
|
| March 20, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Vor Biopharma Inc. |
|
| March 20, 2025 |
100 Cambridgepark Dr, Suite 101 | Cambridge, MA 02140 | vorbio.com Exhibit 10.17 October 4, 2022 Eyal Attar Dear Eyal: On behalf of Vor Biopharma Inc. (“VOR” or the “Company”), I am delighted to offer you the exempt position of Chief Medical Officer, reporting to Robert Ang, President and Chief Executive Officer. Your effective date of hire as an employee will be October 11, 2022, unless another date is agreed to by you and the Company. Your compensation for this |
|
| March 20, 2025 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.6 VOR BIOPHARMA INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF VOR BIOPHARMA INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VOR BIOPHARMA INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of |
|
| March 20, 2025 |
Form of Debt Indenture between the Registrant and one or more trustees to be named Exhibit 4.4 VOR BIOPHARMA INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF [•], 20 DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Section |
|
| March 20, 2025 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.8 VOR BIOPHARMA INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF VOR BIOPHARMA INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VOR BIOPHARMA INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the l |
|
| March 20, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 VOR BIOPHARMA INC. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per share, reserved for issuance pursuant to |
|
| March 20, 2025 |
Power of Attorney (included on the signature page of this registration statement) Table of Contents As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. |
|
| March 20, 2025 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.7 VOR BIOPHARMA INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF VOR BIOPHARMA INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VOR BIOPHARMA INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under th |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARMA |
|
| March 20, 2025 |
As filed with the U.S. Securities and Exchange Commission on March 20, 2025 As filed with the U.S. Securities and Exchange Commission on March 20, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vor Biopharma Inc. (Exact name of Registrant as specified in its charter) Delaware 81-1591163 (State or other jurisdiction of Incorporation or organization) (I.R. |
|
| March 20, 2025 |
Vor Biopharma Inc. Incentive Compensation Recoupment Policy Exhibit 97.1 Vor Biopharma Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Vor Biopharma Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable In |
|
| March 20, 2025 |
VOR BIOPHARMA INC. INSIDER TRADING AND WINDOW PERIOD POLICY Exhibit 19.1 VOR BIOPHARMA INC. INSIDER TRADING AND WINDOW PERIOD POLICY I. Introduction This policy determines acceptable transactions in the securities of Vor Biopharma Inc. (the “Company”) and other publicly-traded companies by our employees, directors and consultants who may become aware of material non-public information (“designated consultants”). During the course of your employment, direct |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| January 29, 2025 |
125,710,335 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-284380 PROSPECTUS 125,710,335 Shares Common Stock This prospectus relates to the proposed resale from time to time by the selling stockholders named herein, together with any additional selling stockholders listed in a prospectus supplement (together with any of such stockholders’ donees, pledgees, transferees or other success |
|
| January 27, 2025 |
VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140 VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140 January 27, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell Re: Vor Biopharma Inc. Registration Statement on Form S-3 (File No. 333-284380) Request for Acceleration of Effective Date Requested Date: January 29, 2025 Re |
|
| January 21, 2025 |
As filed with the Securities and Exchange Commission on January 21, 2025 Table of Contents As filed with the Securities and Exchange Commission on January 21, 2025 Registration No. |
|
| January 21, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Vor Biopharma Inc. |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 8, 2025 |
EX-99.1 Exhibit 99.1 Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors CAMBRIDGE, Mass., January 8, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio’s Board o |
|
| January 7, 2025 |
EX-99.1 2 ex-99-01072025090100.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of January 7, 2025, is by and among Reprogrammed Interchange LLC and Reid Hoffman (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G a |
|
| December 30, 2024 |
EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of December 30, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedu |
|
| December 27, 2024 |
Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 26, 2024, by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and delivering thi |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 27, 2024 |
Form of Registration Rights Agreement. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 26, 2024, is entered into by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used |
|
| December 27, 2024 |
Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REG |
|
| December 27, 2024 |
Exhibit 99.1 Vor Bio Announces $55.6 Million Private Placement Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025 Extends cash runway through release of updated data from VBP101 and VBP301 trials in 2025 CAMBRIDGE, Mass |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| December 9, 2024 |
Exhibit 99.2 Ambition: Curing Blood Cancers through cell and genome engineering 1 December 2024 Disclaimer This presentation (the “Presentation”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. (“Vor,” “Vor Bio” or the “Company”). The words “aim,” “anticipate,” “believe,” “can,” “could,” “design,” “enable” “est |
|
| December 9, 2024 |
Exhibit 99.1 Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design • Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplant • Trem-cel + Mylotar |
|
| November 14, 2024 |
VOR / Vor Biopharma Inc. / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427604d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Vor Biopharma Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 929033108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this statement) Che |
|
| November 7, 2024 |
Offer Letter, by and between the Registrant and Han Choi, dated September 19, 2024 Exhibit 10.1 September 19, 2024 Han Choi Dear Han: On behalf of Vor Biopharma Inc. (“Vor Bio” or the “Company”), I am delighted to offer you the exempt position of Chief Financial Officer, reporting to Robert Ang, President and Chief Executive Officer. Your effective date of hire as an employee will be September 30, 2024 (“Start Date”), unless another date is agreed to by you and the Company. You |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC. |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| September 30, 2024 |
EX-99.1 Exhibit 99.1 Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer CAMBRIDGE, Mass., September 30, 2024 (GLOBE NEWSWIRE)—Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join t |
|
| September 5, 2024 |
September 2024 Ambition: Curing Blood Cancers through cell and genome engineering Exhibit 99. |
|
| September 5, 2024 |
Exhibit 99.1 New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies • Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefit • VCAR33ALLO demonstrates encouraging biomarker data at lowest dose • New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmu |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A Amendment No. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC. |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 28, 2024 |
Amended and Restated 2021 Equity Incentive Plan EX-10.1 Exhibit 10.1 VOR BIOPHARMA INC. AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN Adopted by the Board of Directors: MARCH 26, 2024 APPROVED BY THE STOCKHOLDERS: MAY 23, 2024 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 7 6. ADJUSTMENTS |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC. |
|
| May 2, 2024 |
DEFA14A 1 d819945ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p |
|
| May 2, 2024 |
Exhibit 99.1 Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors CAMBRIDGE, Mass., May 2, 2024 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Researc |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 9, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| March 21, 2024 |
As filed with the U.S. Securities and Exchange Commission on March 20, 2024 S-8 As filed with the U.S. Securities and Exchange Commission on March 20, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vor Biopharma Inc. (Exact name of Registrant as specified in its charter) Delaware 81-1591163 (State or other jurisdiction of Incorporation or organization) |
|
| March 21, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 VOR BIOPHARMA INC. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per share, reserved for issuance pursuant |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARM |
|
| February 14, 2024 |
VOR / Vor Biopharma Inc. / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 tm245955d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Vor Biopharma Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 929033108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this statement) Check |
|
| February 14, 2024 |
VOR / Vor Biopharma Inc. / 5AM Ventures VI, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vor Biopharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 929033108 (CUSIP Number) Paul A. Stone Chief Legal Officer 5AM Venture Management, LLC 501 2nd Street, Suite 350 San Francisco, CA 94107 (415) 99 |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 5, 2024 |
January 2024 Ambition: Curing blood cancers through cell and genome engineering Exhibit 99. |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC. |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 2, 2023 |
Exhibit 99.1 Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform - Three oral and two poster presentations accepted by ASH - Company to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and Chief of the Hematologic Malignancies Program in the Division of Oncology |
|
| August 30, 2023 |
As filed with the U.S. Securities and Exchange Commission on August 30, 2023. As filed with the U.S. Securities and Exchange Commission on August 30, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vor Biopharma Inc. (Exact name of Registrant as specified in its charter) Delaware 81-1591163 (State or other jurisdiction of Incorporation or organization) (I.R.S |
|
| August 30, 2023 |
EX-99.1 Exhibit 99.1 VOR BIOPHARMA INC. 2023 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: AUGUST 25, 2023 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 2 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 6 6. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS 8 7. ADMINISTRA |
|
| August 30, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Vor Biopharma Inc. |
|
| August 11, 2023 |
VOR / Vor Biopharma Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm2323564d1sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* VOR BIOPHARMA INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 929033108 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter K |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC. |
|
| June 9, 2023 |
EX-99.1 Exhibit 99.1 Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform • Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism. • Strong investigator enthusiasm and continued robust enrollment; additional data updates expected by year-end 2023. • U.S. FDA clears VCAR33ALL |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2023 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 11, 2023 |
Non-Employee Director Compensation Policy Exhibit 10.1 Vor Biopharma Inc. Non-Employee Director Compensation Policy Effective: April 12, 2023 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Vor Biopharma Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation P |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC. |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 14, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 14, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARMA |
|
| March 23, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 VOR BIOPHARMA INC. |
|
| March 23, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 23, 2023 S-8 As filed with the U.S. Securities and Exchange Commission on March 23, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vor Biopharma Inc. (Exact name of Registrant as specified in its charter) Delaware 81-1591163 (State or other jurisdiction of Incorporation or organization) (I.R |
|
| February 16, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 16, 2023 |
Exhibit 99.1 First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple MylotargTM Cycles at Initial Dose Level • Trem-cel exhibited robust engraftment five months post-transplant through three cycles of Mylotarg • Mylotarg treatment enriched CD33-negative donor hematopoiesis • Second patient successfully received trem-cel transplant and achieved neutr |
|
| February 14, 2023 |
VOR / Vor Biopharma Inc / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 tm236410d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vor Biopharma Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 929033108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this statement) Check |
|
| December 23, 2022 |
Exhibit 1.1 Execution Version AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT December 23, 2022 STIFEL, NICOLAUS & COMPANY, INCORPORATED 787 Seventh Avenue, 11th Floor New York, New York 10019 Ladies and Gentlemen: Vor Biopharma Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Stifel, Nicolaus & Com |
|
| December 23, 2022 |
Up to $125,000,000 Common Stock Table of Contents PROSPECTUS SUPPLEMENT (To Prospectus Dated March 18, 2022) Up to $125,000,000 Common Stock We have entered into a Sales Agreement, or the sale agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, dated December 23, 2022, relating to the sale of shares of our common stock, $0. |
|
| December 23, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2022 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 16, 2022 |
VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140 VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140 December 16, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jason Drory Re: Vor Biopharma Inc. Registration Statement on Form S-3 (File No. 333-268798) Request for Acceleration of Effective Date Acceleration Request Requested Date: Decemb |
|
| December 14, 2022 |
Termination of a Material Definitive Agreement SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| December 14, 2022 |
EX-FILING FEES 4 d432196dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Vor Biopharma Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amoun |
|
| December 14, 2022 |
As filed with the Securities and Exchange Commission on December 14, 2022 Table of Contents As filed with the Securities and Exchange Commission on December 14, 2022 Registration No. |
|
| December 9, 2022 |
VOR / Vor Biopharma Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* VOR BIOPHARMA INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 929033108 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name, A |
|
| December 8, 2022 |
15,302,267 Shares Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-263541 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 18, 2022) 15,302,267 Shares Common Stock We are offering 15,302,267 shares of our common stock at a purchase price of $4.30 per share. Our common stock is listed on The Nasdaq Global Select Market under the symbol “VOR.” The last reported sale price of our common stock on |
|
| December 7, 2022 |
Exhibit 99.1 Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million CAMBRIDGE, Mass., Dec. 7, 2022 (GLOBE NEWSWIRE) ? Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 |
|
| December 7, 2022 |
Exhibit 99.1 First AML Patient Successfully Transplanted with Vor Bio?s Investigational Trem-cel (VOR33) and Tolerated MylotargTM ? Trem-cel (formerly VOR33) successfully manufactured and engrafted normally ? Blood counts successfully maintained following post-transplant treatment with Mylotarg ? Conference call scheduled for today, December 7 at 8:00am ET CAMBRIDGE, Mass., Dec. 7, 2022 (GLOBE NEW |
|
| December 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| December 7, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| December 7, 2022 |
EX-1.1 2 d411199dex11.htm EX-1.1 Exhibit 1.1 Execution Draft VOR BIOPHARMA INC. Common Stock, par value $0.0001 per share Underwriting Agreement December 7, 2022 Evercore Group L.L.C. Stifel, Nicolaus & Company, Incorporated As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 c/o St |
|
| December 7, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of December 7, 2022, between Vor Biopharma Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions se |
|
| December 7, 2022 |
VBP101 Clinical Update December 7, 2022 Exhibit 99.2 VBP101 Clinical Update December 7, 2022 Disclaimer This presentation (the ?Presentation?) contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. (?Vor,? ?Vor Bio? or the ?Company?) that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in thi |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 14, 2022 |
VOR / Vor Biopharma Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* VOR BIOPHARMA INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 929033108 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name, A |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC. |
|
| October 27, 2022 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0. |
|
| October 27, 2022 |
VOR / Vor Biopharma Inc / Paradigm Biocapital Advisors LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vor Biopharma Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 929033108 (CUSIP Number) October 17, 2022 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designate the rule |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC. |
|
| August 11, 2022 |
Separation Agreement, by and between the Registrant and Christopher Slapak, dated May 11, 2022 Exhibit 10.1 May 11, 2022 Christopher Slapak, M.D. Via DocuSign/Email Re: Separation Agreement Dear Christopher: This letter sets forth the substance of the separation agreement (hereinafter, ?Agreement?) that Vor Biopharma Inc. (hereinafter, the ?Company?) is offering to you to aid in your employment transition and retirement from the Company. 1. Separation. Your last day of employment will be Ma |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC. |
|
| April 28, 2022 |
DEFA14A 1 d268305ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissi |
|
| April 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitte |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 16, 2022 |
VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140 VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140 March 16, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Michael Davis Re: Vor Biopharma Inc. Registration Statement on Form S-3 (File No. 333-263541) Request for Acceleration of Effective Date Acceleration Request Requested Date: March 1 |
|
| March 14, 2022 |
EX-FILING FEES 4 d326176dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 VOR BIOPHARMA INC. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule(1) Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(6) Equity Common Stock, par |
|
| March 14, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 VOR BIOPHARMA INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Fo |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARMA |
|
| March 14, 2022 |
Open Market Sale AgreementSM, dated March 14, 2022, between the Registrant and Jefferies LLC Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM March 14, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Vor Biopharma Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common stock, |
|
| March 14, 2022 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The descriptions below of Vor Biopharma Inc.?s (?we,? ?our? or ?we?) common stock and provisions of our amended and restated certificate of incorporation (?Restated Certificate?) and amended and restated bylaws (?Bylaws?) are summaries and are qualified by reference to ou |
|
| March 14, 2022 |
As filed with the U.S. Securities and Exchange Commission on March 14, 2022 As filed with the U.S. Securities and Exchange Commission on March 14, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vor Biopharma Inc. (Exact name of Registrant as specified in its charter) Delaware 81-1591163 (State or other jurisdiction of Incorporation or organization) (I.R.S. |
|
| March 14, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.6 VOR BIOPHARMA INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF VOR BIOPHARMA INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between VOR BIOPHARMA INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws of |
|
| March 14, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.7 VOR BIOPHARMA INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF VOR BIOPHARMA INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between VOR BIOPHARMA INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under th |
|
| March 14, 2022 |
As filed with the Securities and Exchange Commission on March 14, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 14, 2022 Registration No. |
|
| March 14, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.8 VOR BIOPHARMA INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF VOR BIOPHARMA INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between VOR BIOPHARMA INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the l |
|
| March 14, 2022 |
Form of Debt Indenture between the Registrant and one or more trustees to be named Exhibit 4.4 VOR BIOPHARMA INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF [?], 20 DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certificate 6 Section |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC. |
|
| November 10, 2021 |
EXHIBIT 10.1 Portions of this agreement (indicated by ?[***]?) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT ("Second Amendment") is made and e |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC. |
|
| June 17, 2021 |
Second Amendment to Lease, by and between the Company and Landlord, dated June 15, 2021 Exhibit 10.2 Second Amendment to Lease This Second Amendment to Lease (this ?Amendment?), is made as of the 15th day of June, 2021 (the ?Effective Date?), by and between PPF OFF 100 CAMBRIDGE PARK DRIVE, LLC, a Delaware limited liability company, with a business address of c/o Morgan Stanley Real Estate Advisor, Inc., 1585 Broadway, 37th Floor, New York, New York 10036 (the ?Landlord?) and VOR BIO |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 17, 2021 |
First Amendment to Lease, by and between the Registrant and the Landlord, dated June 15, 2021 Exhibit 10.1 First Amendment to Lease This First Amendment to Lease (this ?Amendment?), is made as of the 15th day of June, 2021 (the ?Effective Date?), by and between PPF OFF 100 CAMBRIDGE PARK DRIVE, LLC, a Delaware limited liability company, with a business address of c/o Morgan Stanley Real Estate Advisor, Inc., 1585 Broadway, 37th Floor, New York, New York 10036 (the ?Landlord?) and VOR BIOPH |
|
| June 17, 2021 |
Exhibit 99.1 Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) - Vor Biopharma (Nasdaq: VOR or the Company) announced today that it will build-out an in-house clinical manufacturing facility in Cambridge, Massachusetts to support its development of potentially transformative engine |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC. |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARMA |
|
| February 19, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Vor Biopharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 929033108 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name, Address |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Vor Biopharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 929033108 (CUSIP Number) 5AM Venture Management, LLC 501 2nd Street, Suite 350 San Francisco, CA 94107 (415) 993-8565 (Name, Address and Telephone |
|
| February 9, 2021 |
S-8 As filed with the U.S. Securities and Exchange Commission on February 9, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vor Biopharma Inc. (Exact name of Registrant as specified in its charter) Delaware 81-1591163 (State or other jurisdiction of Incorporation or organization) (I |
|
| February 9, 2021 |
Amended and Restated Bylaws of the Registrant EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF VOR BIOPHARMA INC. (A DELAWARE CORPORATION) February 9, 2021 VOR BIOPHARMA INC. AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of The Corporation Trust Company, 1209 Orange Street, in the City of Wilmington, County of New Castle, in the State of Del |
|
| February 9, 2021 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 9, 2021 |
Form of Nonstatutory Stock Option Agreement Granted Outside of 2015 Stock Incentive Plan EX-4.7 Exhibit 4.7 VOR BIOPHARMA INC. Nonstatutory Stock Option Agreement Granted Outside of 2015 Stock Incentive Plan 1. Grant of Option. This agreement evidences the grant by Vor Biopharma Inc., a Delaware corporation (the “Company”), [], 2020 (the “Grant Date”) to [] (the “Participant”), of an option to purchase, in whole or in part, on the terms provided herein and subject to the terms of the |
|
| February 9, 2021 |
Amended and Restated Certificate of Incorporation of the Registrant EX-3.1 Exhibit 3.1 VOR BIOPHARMA INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Vor Biopharma Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: FIRST: That the name of this corporation is Vor Biopharma Inc., and that this corporation was originally incorporated pursuant to the General Corporation Law of the S |
|
| February 9, 2021 |
EX-99.1 Exhibit 99.1 Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares CAMBRIDGE, Mass., Feb. 9, 2021 — Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the closing of its previously an |
|
| February 8, 2021 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-252175 and 333-252766 PROSPECTUS 9,828,017 Shares Common Stock This is an initial public offering of shares of common stock of Vor Biopharma Inc. We are offering 9,828,017 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price per share |
|
| February 5, 2021 |
S-1MEF As filed with the Securities and Exchange Commission on February 5, 2021 Registration No. |
|
| February 3, 2021 |
Filed Pursuant to Rule 433 under the Securities Act of 1933 FWP Filed Pursuant to Rule 433 under the Securities Act of 1933 Issuer Free Writing Prospectus dated February 3, 2021 Relating to Preliminary Prospectus issued February 3, 2021 Registration No. |
|
| February 3, 2021 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on February 3, 2021. |
|
| February 2, 2021 |
CORRESP 1 filename1.htm VIA EDGAR February 2, 2021 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Schwartz Joe McCann Eric Atallah Kevin Kuhar Re: Vor Biopharma Inc. Registration Statement on Form S-1 (as amended) (File No. 333-252175) Ladies and Gentlemen: In connection with the above-referenced Registration Stateme |
|
| February 2, 2021 |
Vor Biopharma Inc. 100 Cambridgepark Drive Suite 400 Cambridge, Massachusetts 02140 February 2, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Eric Atallah Kevin Kuhar Joe McCann Margaret Schwartz RE: Vor Biopharma Inc. Registration Statement on Form S-1 File No. 333-252175 Acceleration Request Request |
|
| February 1, 2021 |
EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF VOR BIOPHARMA INC. (A DELAWARE CORPORATION) [ ], 2021 VOR BIOPHARMA INC. AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of The Corporation Trust Company, 1209 Orange Street, in the City of Wilmington, County of New Castle, in the State of Delaware, |
|
| February 1, 2021 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VOR BIOPHARMA INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Vor Biopharma, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That the |
|
| February 1, 2021 |
Executive Severance and Change in Control Benefits Plan EX-10.15 Exhibit 10.15 VOR BIOPHARMA INC. Executive Severance and Change in Control Benefits Plan 1. Establishment of Plan. Vor Biopharma Inc., a Delaware corporation, hereby establishes an unfunded severance benefits plan (the “Plan”) that is intended to be a welfare benefit plan within the meaning of Section 3(1) of ERISA. The Plan is in effect for Covered Employees who experience a Covered Term |
|
| February 1, 2021 |
Non-Employee Director Compensation Policy EX-10.14 Exhibit 10.14 VOR BIOPHARMA INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Vor Biopharma Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or |
|
| February 1, 2021 |
Form of Underwriting Agreement EX-1.1 Exhibit 1.1 VOR BIOPHARMA INC. Common Stock, par value $0.0001 per share Underwriting Agreement [●], 2021 Goldman Sachs & Co. LLC Evercore Group L.L.C. Barclays Capital Inc. Stifel, Nicolaus & Company, Incorporated As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282-2198 c/o Ev |
|
| February 1, 2021 |
2021 Employee Stock Purchase Plan. EX-10.7 Exhibit 10.7 VOR BIOPHARMA INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: January 28, 2021 APPROVED BY THE STOCKHOLDERS: January 29, 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Comp |
|
| February 1, 2021 |
EX-3.3 Exhibit 3.3 VOR BIOPHARMA INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Vor Biopharma Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: FIRST: That the name of this corporation is Vor Biopharma Inc., and that this corporation was originally incorporated pursuant to the General Corporation Law of the S |
|
| February 1, 2021 |
S-1/A 1 d942530ds1a.htm S-1/A Table of Contents As filed with the Securities and Exchange Commission on February 1, 2021. Registration No. 333-252175 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vor Biopharma Inc. (Exact name of registrant as specified in its charter) Delaware 2836 81-159 |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Vor Biopharma Inc. (Exact name of registrant as specified in its charter) Delaware 81-1591163 (State of incorporation or organization) (I.R.S. Employer Identification No.) 100 Cambridgepark Drive S |
|
| February 1, 2021 |
EX-4.2 Exhibit 4.2 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration 4 2.2 Company Registration 6 2.3 Underwriting Requirements 6 2.4 Obligations of the Company 7 2.5 Furnish Information 8 2.6 Expenses of Registration 8 2.7 Delay of Registration 8 2.8 Indemnification 9 2.9 Reports Under Exchange Act 10 2.10 Lim |
|
| February 1, 2021 |
Form of Common Stock Certificate of the Registrant EX-4.1 Exhibit 4.1 PO BOX 505006, Louisville, KY 40233-5006 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 CUSIP/IDENTIFIER XXXXXX XX X Holder ID XXXXXXXXXX Insurance Value 1,000,000.00 Number of Shares 123456 DTC 12345678 123456789012345 Certificate Numbers Num/No. Denom. Total 1234567890/1234567890 1 1 1 1234567890/1234567890 2 2 2 1234567890/1234567890 3 3 3 1234567890/1234567890 4 4 |
|
| February 1, 2021 |
EX-10.6 Exhibit 10.6 VOR BIOPHARMA INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JANUARY 28, 2021 APPROVED BY THE STOCKHOLDERS: JANUARY 29, 2021 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 7 6. ADJUSTMENTS UPON CHANGES I |
|
| February 1, 2021 |
Richard Segal +1 (617) 937-2332 [email protected] VIA EDGAR February 1, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington D.C., 20549 Attn: Eric Atallah Kevin Kuhar Joe McCann Margaret Schwartz Re: Vor Biopharma Inc. Registration Statement on Form S-1 Submitted January 15, 2021 CIK No. 0001817229 Ladies and Gentlemen: On behalf of V |
|
| January 21, 2021 |
Richard Segal +1 617 937 2332 [email protected] BY EDGAR *FOIA Confidential Treatment Request* Confidential Treatment Requested by Vor Biopharma Inc. in connection with Registration Statement on Form S-1 (File No. 333-252175) January 21, 2021 U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Vor Biopharma I |
|
| January 15, 2021 |
EX-10.3 Exhibit 10.3 Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE This Agreement is based on the model Patent License Exclusive Agreem |
|
| January 15, 2021 |
Form of Indemnification Agreement with Executive Officers and Directors EX-10.8 Exhibit 10.8 VOR BIOPHARMA INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of [ ], 20[ ], and is between Vor Biopharma Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or officers of corporat |
|
| January 15, 2021 |
EX-10.1 Exhibit 10.1 Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. EXCLUSIVE LICENSE AGREEMENT This EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), dated April 28, 2016 (the “Effective Date”), is |
|
| January 15, 2021 |
EX-10.2 Exhibit 10.2 Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment”) is made a |
|
| January 15, 2021 |
EX-10.5 Exhibit 10.5 VOR BIOPHARMA INC. 2015 STOCK INCENTIVE PLAN (as amended) 1. Purpose The purpose of this 2015 Stock Incentive Plan (the “Plan”) of Vor Biopharma Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the |
|
| January 15, 2021 |
Amended and Restated Certificate of Incorporation of the Registrant (as currently in effect) EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VOR BIOPHARMA INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Vor Biopharma, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That the |
|
| January 15, 2021 |
Offer Letter, by and between the Registrant and Robert Ang, dated June 28, 2019 EX-10.9 Exhibit 10.9 June 28, 2019 Dear Robert, On behalf of Vor Biopharma Inc. (“VOR” or the “Company”), we are thrilled to offer you the following: 1. You will be employed to serve on a full-time basis as President and Chief Executive Officer of the Company commencing on August 5, 2019 and during the period of your employment in such roles will serve as a member of the Board of Directors of the |
|
| January 15, 2021 |
Offer Letter, by and between the Registrant and Christopher Slapak, dated July 2, 2020 EX-10.11 Exhibit 10.11 July 2, 2020 Dear Christopher, On behalf of Vor Biopharma Inc. (“VOR” or the “Company”), we are thrilled to offer you the following: 1. You will be employed to serve on a full-time basis as Chief Medical Officer of the Company commencing on July 10, 2020 or another date mutually agreed by you and the Company (the actual date you commence employment, the “Start Date”). As Chi |
|
| January 15, 2021 |
Bylaws of the Registrant (currently in effect) EX-3.2 Exhibit 3.2 BY-LAWS OF VOR BIOPHARMA INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 1.10 Conduct of Meetings 3 1.11 Action without Meeting 4 ARTICLE II DIRECTORS 5 2.1 General Powers 5 2.2 Number |
|
| January 15, 2021 |
Offer Letter, by and between the Registrant and Tirtha Chakraboty, dated August 28, 2019 EX-10.13 Exhibit 10.13 Tirtha Chakraboty Dear Tirtha, On behalf of Vor Biopharma Inc. (“VOR” or the “Company”), we are thrilled to offer you the following: 1. You will be employed to serve on a full-time basis as a Vice President-Research commencing on September 23, 2019. As the Vice President- Research, you will be responsible for undertaking such duties and responsibilities inherent in the posit |
|
| January 15, 2021 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on January 15, 2021. |
|
| January 15, 2021 |
EX-10.4 Exhibit 10.4 100 CAMBRIDGEPARK DRIVE CAMBRIDGE, MASSACHUSETTS LEASE Between PPF OFF 100 CAMBRIDGE PARK DRIVE, LLC, a Delaware limited liability company (“LANDLORD”) AND VOR BIOPHARMA, INC., a Delaware corporation (“TENANT”) dated as of December 17, 2019 TABLE OF CONTENTS Page ARTICLE 1 Basic Lease Information 1 ARTICLE 2 Lease Grant 6 ARTICLE 3 Base Building Work; Condition of the Premises |
|
| January 15, 2021 |
Subsidiaries of the Registrant EX-21.1 Exhibit 21.1 Subsidiaries of Vor Biopharma Inc. Name of Subsidiary Jurisdiction of Incorporation Vor Biopharma Securities Corporation Massachusetts |
|
| January 15, 2021 |
Offer Letter, by and between the Registrant and Sadik Kassim, dated August 12, 2019 EX-10.10 Exhibit 10.10 August 12, 2019 Dear Sadik, On behalf of Vor Biopharma Inc. (“VOR” or the “Company”), we are thrilled to offer you the following: 1. You will be employed to serve on a full-time basis as Chief Technology Officer of the Company commencing on September 30, 2019 or another date mutually agreed by you and the Company (the actual date you commence employment, the “Start Date”). A |
|
| January 15, 2021 |
Richard Segal +1 (617) 937-2332 [email protected] VIA EDGAR January 15, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington D.C., 20549 Attn: Eric Atallah Kevin Kuhar Joe McCann Margaret Schwartz Re: Vor Biopharma Inc. Amendment No. 1 to the Draft Registration Statement on Form S-1 Submitted December 18, 2020 CIK No. 0001817229 Ladies |
|
| January 15, 2021 |
Offer Letter, by and between the Registrant and Nathan Jorgensen, dated March 20, 2020 EX-10.12 Exhibit 10.12 March 20, 2020 Dear Nathan, On behalf of Vor Biopharma Inc. (“VOR” or the “Company”), we are thrilled to offer you the following: 1. You will be employed to serve on a full-time basis as Chief Financial Officer of the Company commencing on June 22, 2020 or another date mutually agreed by you and the Company depending on release from current employer (the actual date you comm |
|
| December 18, 2020 |
Richard Segal +1 (617) 937-2332 [email protected] VIA EDGAR December 18, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington D.C., 20549 Attn: Eric Atallah Kevin Kuhar Joe McCann Margaret Schwartz Re: Vor Biopharma Inc. Draft Registration Statement on Form S-1 Submitted November 6, 2020 CIK No. 0001817229 Ladies and Gentlemen: On beha |
|
| December 18, 2020 |
EX-10.1 2 filename2.htm Exhibit 10.1 Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. EXCLUSIVE LICENSE AGREEMENT This EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), dated April 28, 2016 (the “Effe |
|
| December 18, 2020 |
Table of Contents As submitted to the Securities and Exchange Commission confidentially on December 18, 2020. |
|
| December 18, 2020 |
FIRST AMENDMENT EXCLUSIVE LICENSE AGREEMENT EX-10.2 Exhibit 10.2 Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment”) is made a |
|
| December 18, 2020 |
Exhibit 21.1 Subsidiaries of Vor Biopharma Inc. Name of Subsidiary Jurisdiction of Incorporation Vor Biopharma Securities Corporation Massachusetts |
|
| December 18, 2020 |
EX-10.3 4 filename4.htm Exhibit 10.3 Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE This Agreement is based on the model Patent License |
|
| November 6, 2020 |
Table of Contents As submitted to the Securities and Exchange Commission confidentially on November 6, 2020. |
|
| November 6, 2020 |
Exhibit 10.9 June 28, 2019 Dear Robert, On behalf of Vor Biopharma Inc. (?VOR? or the ?Company?), we are thrilled to offer you the following: 1. You will be employed to serve on a full-time basis as President and Chief Executive Officer of the Company commencing on August 5, 2019 and during the period of your employment in such roles will serve as a member of the Board of Directors of the Company |
|
| November 6, 2020 |
Employee Proprietary Information and Inventions Assignment Agreement Exhibit 10.12 March 20, 2020 Dear Nathan, On behalf of Vor Biopharma Inc. (?VOR? or the ?Company?), we are thrilled to offer you the following: 1. You will be employed to serve on a full-time basis as Chief Financial Officer of the Company commencing on June 22, 2020 or another date mutually agreed by you and the Company depending on release from current employer (the actual date you commence empl |
|
| November 6, 2020 |
Employee Proprietary Information and Inventions Assignment Agreement Exhibit 10.11 July 2, 2020 Dear Christopher, On behalf of Vor Biopharma Inc. (?VOR? or the ?Company?), we are thrilled to offer you the following: 1. You will be employed to serve on a full-time basis as Chief Medical Officer of the Company commencing on July 10, 2020 or another date mutually agreed by you and the Company (the actual date you commence employment, the ?Start Date?). As Chief Medica |
|
| November 6, 2020 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VOR BIOPHARMA INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Vor Biopharma, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That the name of |
|
| November 6, 2020 |
VOR BIOPHARMA INC. 2015 STOCK INCENTIVE PLAN (as amended) EX-10.5 4 filename4.htm Exhibit 10.5 VOR BIOPHARMA INC. 2015 STOCK INCENTIVE PLAN (as amended) 1. Purpose The purpose of this 2015 Stock Incentive Plan (the “Plan”) of Vor Biopharma Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important cont |
|
| November 6, 2020 |
EX-3.2 3 filename3.htm Exhibit 3.2 BY-LAWS OF VOR BIOPHARMA INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 1.10 Conduct of Meetings 3 1.11 Action without Meeting 4 ARTICLE II DIRECTORS 5 2.1 General Pow |
|
| November 6, 2020 |
Employee Proprietary Information and Inventions Assignment Agreement Exhibit 10.10 August 12, 2019 Dear Sadik, On behalf of Vor Biopharma Inc. (?VOR? or the ?Company?), we are thrilled to offer you the following: 1. You will be employed to serve on a full-time basis as Chief Technology Officer of the Company commencing on September 30, 2019 or another date mutually agreed by you and the Company (the actual date you commence employment, the ?Start Date?). As Chief T |
